In our analysis, there were no statistically significant differences in the clinical characteristics between HER2-positive and HER2-negative populations, but we found a trend for HER2-positive to be younger, less frequently affected by adenocarcinoma NOS, and more frequently affected by CNS metastases. The gene discussed is ERBB2; the disease is adenocarcinoma.